Form 4: Cumberland Pharmaceuticals Director Caroline Young Acquires 1,000 Shares
SEC Form 4 Filing
Director Caroline Young acquired 1,000 shares of Cumberland Pharmaceuticals stock at $1.71 per share on March 25, 2024.
Summary
- Caroline Young, a director of Cumberland Pharmaceuticals, acquired 1,000 shares of common stock on March 25, 2024.
- The purchase price was $1.71 per share.
- Following the transaction, Ms. Young directly owns 26,701 shares of Cumberland Pharmaceuticals.
- The acquisition was a restricted stock award that will vest 100% on March 25, 2025.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of a director's stock purchase. While insider buying can be seen as a positive signal, the amount is not significant enough to drastically alter sentiment.
Positives
- The director's purchase could be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider transactions are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future performance. This transaction is a routine disclosure of insider activity.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of transaction: Caroline Young acquired 1,000 shares of Cumberland Pharmaceuticals. |
| 03/25/2025 | Vesting date of the restricted stock award. |
| 03/26/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.